ECL Stock Recent News

Ecolab Inc ECL reported worse-than-expected second-quarter earnings on Tuesday.

I reiterate a Sell rating on Ecolab Inc., due to ongoing weak demand in heavy industrial and paper markets despite management's effective margin expansion strategies. Q2 FY25 results showed modest 3% organic revenue growth and 13% adj. EPS growth, driven by value pricing and cost optimization amid soft end-market demand. My DCF analysis yields a fair value of $218 per share, indicating overvaluation at current levels, even as management targets higher margins and EPS growth.

Ecolab, Inc. (NYSE:ECL ) Q2 2025 Earnings Conference Call July 29, 2025 1:00 PM ET Company Participants Andrew Hedberg - Director of Investor Relations Christophe Beck - CEO & Chairman of the Board Scott D. Kirkland - Chief Financial Officer Conference Call Participants Andrew John Wittmann - Robert W.

ECL stock dips in pre-market despite second-quarter 2025 earnings growth and margin expansion, as EPS misses estimates by a penny.

Shares of leading sustainability juggernaut Ecolab (ECL -4.59%) were down 4% at 11 a.m. ET on Tuesday, according to data provided by S&P Global Market Intelligence.

Ecolab (ECL -3.83%), a global leader in water, hygiene, and infection prevention solutions, reported its financial results for the second quarter of fiscal 2025 on July 29, 2025. The company delivered GAAP revenue of $4.03 billion, while adjusted diluted earnings per share increased 13% to $1.89, just below the $1.90 consensus.

Although the revenue and EPS for Ecolab (ECL) give a sense of how its business performed in the quarter ended June 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Ecolab (ECL) came out with quarterly earnings of $1.89 per share, missing the Zacks Consensus Estimate of $1.9 per share. This compares to earnings of $1.68 per share a year ago.

ST. PAUL, Minn.--(BUSINESS WIRE)--Ecolab Inc. (NYSE: ECL): SECOND QUARTER HIGHLIGHTS Ecolab delivered another strong quarter of double-digit EPS growth, consistent with expectations. This superior performance was fueled by continued value pricing, volume growth, and productivity improvements. Reported sales $4.0 billion, +1%, including a 2% unfavorable impact from the sale of the global surgical solutions business. Organic sales +3%, led by continued strong growth in the Institutional & Spe.

Ecolab rides momentum in Global Water and Pest Elimination, but macroeconomic headwinds may test its second-quarter 2025 earnings strength.